Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1501

1.

Multiple sclerosis: Hematopoietic mobilization-a potential circulating biomarker for natalizumab response.

[No authors listed]

Nat Rev Neurol. 2015 Mar 24. doi: 10.1038/nrneurol.2015.42. [Epub ahead of print] No abstract available.

PMID:
25799929
2.

Therapeutic management of severe relapses in multiple sclerosis.

Bevan C, Gelfand JM.

Curr Treat Options Neurol. 2015 Apr;17(4):345. doi: 10.1007/s11940-015-0345-6.

PMID:
25794777
3.

Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.

Cobo-Calvo Á, Bau L, Matas E, Romero-Pinel L, Mañé Martínez MA, Majós C, Martínez Yélamos S.

Eur Neurol. 2015 Mar 13;73(3-4):220-229. [Epub ahead of print]

PMID:
25792347
4.

Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.

Amato MP, Portaccio E.

CNS Drugs. 2015 Mar 14. [Epub ahead of print]

PMID:
25773609
5.

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.

Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB.

J Neurovirol. 2015 Mar 14. [Epub ahead of print]

PMID:
25771865
6.

Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.

Mattoscio M, Nicholas R, Sormani MP, Malik O, Lee JS, Waldman AD, Dazzi F, Muraro PA.

Neurology. 2015 Mar 11. pii: 10.1212/WNL.0000000000001454. [Epub ahead of print]

PMID:
25762712
7.

Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis.

Lin L, Liu X, Wang D, Zheng C.

Medicine (Baltimore). 2015 Mar;94(10):e556. doi: 10.1097/MD.0000000000000556.

PMID:
25761174
8.

Effects of Immunosuppressants on Immune Response to Vaccine in Inflammatory Bowel Disease.

Cao Y, Zhao D, Xu AT, Shen J, Ran ZH.

Chin Med J (Engl). 2015 20th Mar;128(6):835-838. doi: 10.4103/0366-6999.152683.

9.

Cytokines and chemokines in multiple sclerosis.

Mazzi V.

Clin Ter. 2015 Jan-Feb;166(1):e62-6.

PMID:
25756269
10.

Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness.

Penner IK, Sivertsdotter EC, Celius EG, Fuchs S, Schreiber K, Berkö S, Svenningsson A; TYNERGY trial investigators.

Front Neurol. 2015 Feb 23;6:18. doi: 10.3389/fneur.2015.00018. eCollection 2015.

11.

Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Wiebenga OT, Klauser AM, Schoonheim MM, Nagtegaal GJ, Steenwijk MD, van Rossum JA, Polman CH, Barkhof F, Pouwels PJ, Geurts JJ.

AJNR Am J Neuroradiol. 2015 Mar 5. [Epub ahead of print]

PMID:
25742985
12.

Switching therapies in MS: what are the options?

Markowitz CE.

J Clin Psychiatry. 2015 Feb;76(2):e6. doi: 10.4088/JCP.13037nr2c.

13.

Immunology of progressive multifocal leukoencephalopathy.

Jelcic I, Jelcic I, Faigle W, Sospedra M, Martin R.

J Neurovirol. 2015 Mar 5. [Epub ahead of print]

PMID:
25740538
14.

[Monoclonal antibodies for the treatment of multiple sclerosis].

Sánchez-Seco VG, Casanova Peño I, Arroyo González R.

Med Clin (Barc). 2014 Dec;143 Suppl 3:30-4. doi: 10.1016/S0025-7753(15)30007-5. Spanish.

PMID:
25732947
15.

Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.

McQueen RB, Livingston T, Vollmer T, Corboy J, Buckley B, Allen RR, Nair K, Campbell JD.

J Manag Care Spec Pharm. 2015 Mar;21(3):210-8.

16.

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.

[No authors listed]

Neurology. 2015 Feb 24;84(8):862. doi: 10.1212/WNL.0000000000001255. No abstract available.

PMID:
25713117
17.

Severe anemia in a patient with multiple sclerosis treated with natalizumab.

Seibert JB, Alvarez E.

Neurology. 2015 Feb 24;84(8):861. doi: 10.1212/01.wnl.0000461938.49936.52. No abstract available.

PMID:
25713115
18.

B cell VLA-4-deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity.

Lehmann-Horn K, Sagan SA, Bernard CC, Sobel RA, Zamvil SS.

Ann Neurol. 2015 Feb 23. doi: 10.1002/ana.24387. [Epub ahead of print]

PMID:
25712734
19.

NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis.

Duddy M.

Neurodegener Dis Manag. 2015 Feb;5(1):7-10. doi: 10.2217/nmt.14.50. No abstract available.

20.

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.

Lane MA, Renga V, Pachner AR, Cohen JA.

Case Rep Neurol Med. 2015;2015:892047. doi: 10.1155/2015/892047. Epub 2015 Jan 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk